Progressive Multifocal Leukoencephalopathy: Current Insights

Show full item record



Permalink

http://hdl.handle.net/10138/309236

Citation

Kartau , M , Sipilä , J O T , Auvinen , E , Palomäki , M & Verkkoniemi-Ahola , A 2019 , ' Progressive Multifocal Leukoencephalopathy: Current Insights ' , Neurodegenerative Diseases , vol. 9 , pp. 109-121 . https://doi.org/10.2147/DNND.S203405

Title: Progressive Multifocal Leukoencephalopathy: Current Insights
Author: Kartau, Marge; Sipilä, Jussi O. T.; Auvinen, Eeva; Palomäki, Maarit; Verkkoniemi-Ahola, Auli
Contributor: University of Helsinki, Department of Neurosciences
University of Helsinki, Medicum
University of Helsinki, HUS Medical Imaging Center
University of Helsinki, HUS Neurocenter
Date: 2019-12-02
Language: eng
Number of pages: 13
Belongs to series: Neurodegenerative Diseases
ISSN: 1660-2854
URI: http://hdl.handle.net/10138/309236
Abstract: Cases of PML should be evaluated according to predisposing factors, as these subgroups differ by incidence rate, clinical course, and prognosis. The three most significant groups at risk of PML are patients with hematological malignancies mostly previously treated with immunotherapies but also untreated, patients with HIV infection, and patients using monoclonal antibody (mAb) treatments. Epidemiological data is scarce and partly conflicting, but the distribution of the subgroups appears to have changed. While there is no specific anti-JCPyV treatment, restoration of the immune function is the most effective approach to PML treatment. Research is warranted to determine whether immune checkpoint inhibitors could benefit certain PML subgroups. There are no systematic national or international records of PML diagnoses or a risk stratification algorithm, except for MS patients receiving natalizumab (NTZ). These are needed to improve PML risk assessment and to tailor better prevention strategies.
Subject: 3124 Neurology and psychiatry
progressive multifocal leukoencephalopathy
JC polyomavirus
monoclonal antibodies
HIV
multiple sclerosis
disease modifying therapies
SYSTEMIC-LUPUS-ERYTHEMATOSUS
MULTIPLE-SCLEROSIS
JC-VIRUS
CELL TRANSPLANTATION
RISK
PML
THERAPY
DISORDERS
INFECTION
SURVIVAL
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
dnnd_203405_pro ... pathy_current_insights.pdf 448.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record